Read by QxMD icon Read

Anticancer Research

(no author information available yet)
No abstract text is available yet for this article.
November 2017: Anticancer Research
(no author information available yet)
No abstract text is available yet for this article.
November 2017: Anticancer Research
Ciprian Cirimbei, Vlad Rotaru, Elena Chitoran, Oana Pavaleanu, Simona Elena Cirimbei
BACKGROUND/AIM: Radiofrequency ablation (RFA) of colorectal liver metastases (CRLMs) is a method developed in the last 15 years. It provides an acceptable control of the malignant process with lower risks compared to surgical resection. The aim of the study was to assess immediate and long-term results, including recurrence, survival, morbidity/mortality rates after RFA. PATIENTS AND METHODS: Sixty-two cases with CRLMs were treated by RFA during open surgery (89 lesions)...
November 2017: Anticancer Research
Akira Matsui, Akihiko Tatibana, Noriyuki Suzuki, Masaru Hirata, Yoko Oishi, Youhei Hamaguchi, Yuya Murata, Aiko Nagayama, Yuko Iwata, Yasushi Okamoto
BACKGROUND: Taxanes are among the key drugs for breast cancer treatment. This study aimed to evaluate the efficacy of upfront weekly nanoparticle albumin-bound paclitaxel (Nab-PTX; 100 mg/m(2)) for human epidermal growth factor 2 (HER2)-negative breast cancer. PATIENTS AND METHODS: Patients with stage II to IV breast cancer received 12 cycles of weekly 100 mg/m(2) Nab-PTX as first-line treatment. Preoperative chemotherapy with anthracyclines after Nab-PTX was recommended...
November 2017: Anticancer Research
Yuko Oya, Tatsuya Yoshida, Hiroaki Kuroda, Junichi Shimizu, Yoshitsugu Horio, Yukinori Sakao, Toyoaki Hida, Yasushi Yatabe
Several second-generation inhibitors of anaplastic lymphoma kinase (ALK) have demonstrated potent activity in ALK rearrangement-positive non-small cell lung cancer (NSCLC). Two of these agents, ceritinib, and alectinib, recently received approval for the treatment of ALK-rearranged NSCLC in Japan. The efficacy of treatment with a second-generation ALK inhibitor after failure with a different second-generation ALK inhibitor remains unclear. We present a series of eight patients with ALK-rearranged NSCLC treated with alectinib who experienced disease progression after ceritinib...
November 2017: Anticancer Research
Ondrej Fiala, Petr Hosek, Milos Pesek, Jindrich Finek, Jaroslav Racek, Pavel Stehlik, Ondrej Sorejs, Marek Minarik, Lucie Benesova, Adam Celer, Ivana Nemcova, Radek Kucera, Ondrej Topolcan
BACKGROUND: Erlotinib is a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR); it is used in the treatment of advanced non-small cell lung cancer (NSCLC). We focused on the role of serum concentration of erlotinib and its association with outcome and toxicity in patients with advanced NSCLC harbouring the wild-type EGFR gene or squamous histology. PATIENTS AND METHODS: Clinical data of 122 patients were analyzed. Serum samples were collected within four weeks after the initiation of treatment...
November 2017: Anticancer Research
Tatsuhiro Kajitani, Akitaka Makiyama, Shuji Arita, Hozumi Shimokawa, Hisanobu Oda, Tsuyoshi Shirakawa, Eishi Baba, Taito Esaki
BACKGROUND/AIM: Readministration of anti-epidermal growth factor receptor (EGFR) antibody for metastatic colorectal cancer (mCRC) after disease progression remains to be determined. PATIENTS AND METHODS: Readministration of anti-EGFR antibody in mCRC patients previously refractory to anti-EGFR antibody was prospectively observed. RESULTS: A total of thirteen patients with a median age of 60-years old and an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, were enrolled...
November 2017: Anticancer Research
Giovanni Schinzari, Santa Monterisi, Francesco Pierconti, Giulia Nazzicone, Laura Marandino, Armando Orlandi, Marco Racioppi, Alessandra Cassano, Pierfrancesco Bassi, Carlo Barone, Ernesto Rossi
BACKGROUND: Neoadjuvant chemotherapy demonstrated a survival benefit versus cystectomy alone in muscle-invasive urothelial bladder cancer. Despite this advantage, preoperative chemotherapy is not widely employed. When patients are unfit for cisplatin-based regimen, they are often candidates for immediate surgery. In our study, patients with muscle-invasive bladder cancer were treated with neoadjuvant chemotherapy. The principal objective was the rate of complete pathological response (pCR)...
November 2017: Anticancer Research
Chuang-Chi Liaw, Cheng-Keng Chuang, Ying-Hsu Chang, Tzu-Yao Liao, John Wen-Cheng Chang, Yu-Hsiang Juan
AIM: We investigated bladder urothelial carcinoma with peritoneal involvement. PATIENTS AND METHODS: Inclusion criteria were: pathology-confirmed urothelial carcinoma; peritoneal spread identified on computed tomographic (CT) scans performed initially or after either cystectomy or concomitant chemoradiotherapy (CCRT), and absence of visceral metastases; and chemotherapy administered after peritoneal spread was diagnosed. RESULTS: Forty-seven cases included initial modes of therapy with chemotherapy in 24 patients (51%), cystectomy in 17 (36%), and CCRT in six (13%), only given as a result of under-staging...
November 2017: Anticancer Research
Hendrik Heers, Patrick DE Geeter, Peter J Goebell, Ullrich Matz, Wito DE Schultz, Birgit Edlich, Margitta Retz, Axel Hegele
BACKGROUND/AIM: Despite an expected prognostic disadvantage for upper tract versus lower tract metastatic urothelial carcinomas (UTUC/LTUC), only few studies have been conducted to elucidate potential differences in chemotherapy treatment. PATIENTS AND METHODS: A post-hoc subgroup analysis of a non-interventional study investigating vinflunine after failure of a platinum-based chemotherapy in metastatic/locally advanced UC patients was performed. RESULTS: A total of 18 and 59 out of 77 patients had UTUC and LTUC, respectively...
November 2017: Anticancer Research
Beatriz Wills, Andrés F Cardona, Leonardo Rojas, Alejandro Ruiz-Patiño, Oscar Arrieta, Noemí Reguart, Hernán Carranza, Carlos Vargas, Jorge Otero, Luis Corrales, Claudio Martín, Mauricio Cuello, Luis Eduardo Pino, Christian Rolfo, Rafael Rosell, Zyanya Lucia Zatarain-Barrón
BACKGROUND: Heavily treated patients with non-small cell lung cancer (NSCLC) have few treatment options, while irinotecan and bevacizumab have proven synergistic action in preclinical studies. PATIENTS AND METHODS: A total of 49 patients with heavily treated NSCLC were enrolled from 2011-2014 and treated with irinotecan and bevacizumab. Treatment response along with mutational status of epidermal growth factor receptor (EGFR), and tissue inhibitor of metalloproteinases-1 (TIMP1) and EGFR expression were evaluated...
November 2017: Anticancer Research
Yuji Morine, Mitsuo Shimada, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Y U Saito, Shinichiro Yamada, Satoru Imura
BACKGROUND/AIM: The aim of this retrospective study was to clarify the effectiveness of chemotherapy with gemcitabine combined with low-dose 5-fluorouracil and cisplatin (GFP) for advanced biliary carcinoma after hepatectomy. PATIENTS AND METHODS: Sixty-two patients had biliary carcinoma with lymph node metastasis, intrahepatic metastasis or positive surgical margins, including intrahepatic cholangiocarcinoma (IHC, n=25), hilar cholangiocarcinoma (HC, n=14), and gallbladder cancer (GBC, n=23)...
November 2017: Anticancer Research
Ishfaq Ahmad Sheikh, Essam Hussain Jiffri, Mohammad Amjad Kamal, Ghulam Md Ashraf, Mohd Amin Beg
BACKGROUND: Lactoperoxidase (LPO) is an antimicrobial protein secreted from mammary, salivary and other mucosal glands. It is an important member of heme peroxidase enzymes and the primary peroxidase enzyme present in breast tissues. In addition to the antimicrobial properties, LPO has been shown to be associated with breast cancer etiology. Heterocyclic amines, an important class of environmental and dietary carcinogens, have been increasingly associated with breast cancer etiology. Heterocyclic amines undergo activation in breast tissue as a result of oxidation by LPO...
November 2017: Anticancer Research
Shouko Nakai, Takahiro Imaizumi, Takahiro Watanabe, Yumiko Iwase, Koji Nishi, Kazuho Okudaira, Nagahiko Yumita
Lomefloxacin (LFX) is a widely used fluoroquinolone antimicrobial agent that plays an important role in the treatment of human and animal infections; however, it has been reported to cause phototoxicity. In this study, we investigated the induction of apoptosis due to ultraviolet A (UVA) light in the presence and absence of LFX in HL-60 human promyelocytic leukemia cells. HL-60 cells were exposed to UVA at an intensity of 1.1 mW/cm(2) for 20 min in the presence and absence of LFX, and the induction of apoptosis was examined by analyzing cell morphology, DNA fragmentation, and caspase-3 activity...
November 2017: Anticancer Research
Yoshikazu Kanazawa, Takeshi Yamada, Itsuo Fujita, Daisuke Kakinuma, Kunihiko Matsuno, Hiroki Arai, Tomohiro Shimoda, Kazuhide Ko, Shunji Kato, Takeshi Matsutani, Nobutoshi Hagiwara, Tsutomu Nomura, Eiji Uchida
AIM: Cisplatin plus 5-fluorouracil (5-FU) or S-1 is a standard therapy for gastric cancer (GC). However, cisplatin is emetic and potentially nephrotoxic. Oxaliplatin may be less toxic, but few basic data are available for this setting. Here, we evaluated oxaliplatin for GC, by testing surgical specimens. MATERIALS AND METHODS: We evaluated effects of oxaliplatin and 5-FU, alone and in combination, on surgical specimens from 11 patients with GC, using collagen gel droplet embedded culture drug tests...
November 2017: Anticancer Research
Pei-Yu Chou, Min-Min Lee, Sung-Yuan Lin, Ming-Jyh Sheu
Pipoxolan is frequently prescribed as a smooth muscle relaxant. Pipoxolan has also been shown to have anticancer activity. Our study investigated whether pipoxolan induced apoptosis in oral squamous cell carcinoma (OSCC). Cell cytotoxicity was evaluated by the MTT assay. Cell apoptosis and cell-cycle distribution were measured by annexin V/propidium iodide (PI) double staining and flow cytometry, respectively. Apoptotic-related proteins were assessed by western blotting. Reactive oxygen species (ROS) generation and mitochondrial membrane potential (MMP) were measured with fluorescent probes...
November 2017: Anticancer Research
Nuray Uremis, Muhammed Mehdi Uremis, Fatma Inanc Tolun, Mustafa Ceylan, Adem Doganer, Akif Hakan Kurt
Pancreatic cancer is one of the deadliest malignancies characterized by strong resistance to almost all chemotherapeutic agents and radiotherapy. In this study, we aimed to investigate the anticancer effect, enzymatic antioxidant activity [superoxide dismutase (SOD), glutathione peroxidase (GPx)] and total antioxidant capacity (TAC) of synthesized benzothiazole compounds against adenocarcinoma cancer cells (PANC-1). 2-((1S,2S)-2-((E)-4-nitrostyryl)cyclopent-3-en-1-yl)benzo[d]thiazole and 2-((1S,2S)-2-((E)-4-fluorostyryl) cyclopent-3-en-1-yl)benzo[d]thiazole containing 2-substituted benzothiazole group were synthesized in two steps...
November 2017: Anticancer Research
Katarzyna Śladowska, Małgorzata Opydo-Chanek, Teodora Król, Wojciech Trybus, Ewa Trybus, Anna Kopacz-Bednarska, Jadwiga Handzlik, Katarzyna Kieć-Kononowicz, Lidia Mazur
BACKGROUND/AIM: To search for new antileukemic agents, the chemical structure of phenytoin was modified. A possible cytotoxic activity of three bromoalkyl phenytoin analogs, methyl 2-(1-(3-bromopropyl)-2,4-dioxo-5,5-diphenylimidazolidin-3-yl) propanoate (PH2), 1-(3-bromopropyl)-3-methyl-5,5-diphenylimidazolidine-2,4-dione (PH3) and 1-(4-bromobutyl)-3-methyl-5,5-diphenylimidazolidine-2,4-dione (PH4) on regulated cell death, the cell cycle and cell ultrastructure was assessed. MATERIALS AND METHODS: The experiments were performed in vitro on HL-60 and U937 cells, using flow cytometry and electron microscopy methods...
November 2017: Anticancer Research
Lidia Mazur, Małgorzata Opydo-Chanek, Katarzyna Śladowska, Barbara Janota, Urszula Kłaput, Małgorzata Łukawska, Irena Oszczapowicz
BACKGROUND/AIM: Epidoxorubicin is an anthracycline agent. The present study was undertaken to compare the antileukemic potential of epidoxorubicin and its two formamidine analogs containing either a morpholine moiety (EPIFmor) or a hexamethyleneimine moiety (EPIFhex) in the amidine group. MATERIALS AND METHODS: The experiments were performed in vitro on MOLT-4 cells using spectrophotometry, Coulter electrical impedance, flow cytometry, and light microscopy methods...
November 2017: Anticancer Research
Malgorzata Opydo-Chanek, Katarzyna Śladowska, Kamil Blicharski, Jaromir Mikeš, Peter Fedoročko, Ulf Niemeyer, Lidia Mazur
BACKGROUND/AIM: The oxazaphosphorines, ifosfamide and cyclophosphamide, represent a class of alkylating agents. The aim of the present in vitro study was to compare antileukemic activity of 4-hydroperoxyifosfamide (4-OOH-IF) and 4-hydroperoxycyclophosphamide (4-OOH-CP). MATERIALS AND METHODS: The experiments were performed on MOLT-4 and ML-1 cells. The research was conducted using flow cytometry fluorescein diacetate/propidium iodide (PI), fluorescein-conjugated annexin V/PI, CaspGLOW Red Active Caspase-8 and -9, CellEvent™ Caspase-3/7 Green assays, and tetramethylrhodamine ethyl ester test...
November 2017: Anticancer Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"